Adverse side effects are not frequently reported among patients
[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH), or cortisol, and is highly selective for inducing the secretion only of GH
There is a lot left to understand but were hopeful we can translate these discoveries to new therapies. Several sources funded the research, including the Wilmot Cancer Institute, the American Association for Cancer Research and Breast Cancer Research Foundation, Breast Cancer Coalition of Rochester, American Cancer Society, and the National Institutes of Health
This lack of effect on stress hormones was evident even at doses more than 200-fold higher than the ED50 for growth hormone release, establishing ipamorelin as the first GHRP-receptor agonist with selectivity for growth hormone release similar to GHRH itself